As detailed in Supplementary Table 2, nearly all these tests (90/98; 92%) were either for NSCLC patients harboring KRAS mutations indicating they should not receive targeted EGFR tyrosine kinase inhibitors (60/98; 61%), or for colorectal cancer patients harboring KRAS and/or NRAS mutations (32/98; 33%) indicating they should not receive cetuximab and/or panitumumab. This evidence concerns the gene NRAS and colorectal cancer.